zilucoplan sodium - Profile

What are the generic drug sources for zilucoplan sodium and what is the scope of patent protection?

Zilucoplan sodium is the generic ingredient in one branded drug marketed by Ucb Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Zilucoplan sodium has one hundred and fifty-five patent family members in thirty-three countries.

Summary for zilucoplan sodium

International Patents:	155
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for zilucoplan sodium

Constraining patent/regulatory exclusivity:

11,535,650

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for zilucoplan sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-001	Oct 17, 2023		RX	Yes	Yes	11,752,190		Y
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-001	Oct 17, 2023		RX	Yes	Yes	11,014,965			Y
Ucb Inc	ZILBRYSQ	zilucoplan sodium	SOLUTION;SUBCUTANEOUS	216834-001	Oct 17, 2023		RX	Yes	Yes	10,435,438			Y

International Patents for zilucoplan sodium

Country	Patent Number	Title	Estimated Expiration
Australia	2015274482
Australia	2019200828
Australia	2021204313

Supplementary Protection Certificates for zilucoplan sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3154561	CR 2024 00021	Denmark		PRODUCT NAME: ZILUCOPLAN; REG. NO/DATE: EU/1/23/1764 20231204
3154561	PA2024514,C3154561	Lithuania		PRODUCT NAME: ZILUKOPLANAS; REGISTRATION NO/DATE: EU/1/23/1764 20231201
3154561	301275	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE

Zilucoplan Sodium Investment Scenario and Fundamentals Analysis

Last updated: February 21, 2026

What is Zilucoplan Sodium?

Zilucoplan sodium is a complement component 5 (C5) inhibitor developed by UCB Pharma. It is designed to treat autoimmune disorders such as generalized myasthenia gravis (gMG), a neuromuscular disease. The drug functions by blocking complement activation that damages healthy tissue in immune-mediated diseases.

Development Status and Regulatory Pathway

Date/Stage	Details
Phase 3 Trials	Completed for generalized myasthenia gravis (gMG)
Regulatory Submission	UCB filed for approval in the U.S. in Q4 2022
FDA Decision	Anticipated in Q4 2023 or Q1 2024

UCB's Phase 3 trial data demonstrated significant improvement in patient outcomes. The FDA's review is ongoing, with a standard review period opening at the end of 2022.

Market Opportunity and Competitive Landscape

Addressable Market

• Target Disease: Generalized myasthenia gravis (gMG)
• Prevalence: Estimated 20-25 per 100,000 globally
• US Prevalence: Approx. 60,000 cases
• Market Penetration Potential: 50-70% of treated patients could adopt Zilucoplan upon approval

Existing Treatments and Differentiation

Therapy	Mechanism	Market Share	Limitations
Eculizumab	C5 inhibitor, IV infusion	Dominates	High cost, IV administration
Ravulizumab	C5 inhibitor, IV infusion	Growing	Similar limitations, higher cost
Zilucoplan	C5 inhibitor, subcutaneous route	Potential	Oral or self-administered option

Zilucoplan offers subcutaneous administration, potentially reducing treatment costs and improving patient compliance.

Financial and Investment Fundamentals

Revenue Projections

Assuming approval in 2024, conservative U.S. market penetration estimates project:

Year	Patients (thousands)	Market Penetration	Revenue (USD millions)
2024	30	10%	150
2025	60	20%	600
2026	100	30%	1,500

Pricing assumptions:

• Annual treatment cost: $100,000 to $150,000
• U.S. market share: Based on competitive dynamics and unmet needs

Cost Considerations

• Manufacturing costs for biologics are high but declining with scale.
• Commercialization expenses are substantial, particularly for orphan drugs.
• R&D expenses already incurred, with additional costs for post-approval studies.

Investment Risks and Opportunities

Risks	Details
Approval delay or denial	Regulatory setbacks could impact valuation
Market competition	Existing C5 inhibitors with established approvals could limit market share
Pricing pressure	Payers may negotiate discounts, affecting revenue projections

Opportunities	Details
First-in-class potential	If approved, Zilucoplan could secure early adoption in gMG market
Broadening indications	Potential exploration for other complement-mediated diseases
Patient preference	Subcutaneous route may lead to better adherence

Strategic Considerations for Investors

• Regulatory timeline: Approval expected late 2023 or early 2024 influences valuation models.
• Commercial strategy: UCB’s experience and existing infrastructure in neurology can accelerate uptake.
• Pricing policies: Payers' reimbursement landscape and pricing flexibility will shape revenue potential.

Key Takeaways

• Zilucoplan sodium is in late-stage development for gMG with regulatory submission already underway.
• The drug’s subcutaneous delivery could distinguish it from existing IV therapies, potentially capturing significant market share.
• The US market could generate revenues of approximately $150 million in 2024, scaling to over $1.5 billion by 2026 with scalable adoption.
• Competitive threats include existing C5 inhibitors and payer pressure that could limit price growth.
• The success of commercialization hinges on regulatory approval, reimbursement negotiations, and market acceptance.

FAQs

1. When is Zilucoplan expected to receive FDA approval?
Approval is anticipated in late 2023 or early 2024, pending FDA review outcomes.

2. What are the main competitors to Zilucoplan?
Eculizumab (Soliris) and ravulizumab (Ultomiris) are the primary competitors, both administered intravenously.

3. How does Zilucoplan’s route of administration impact its market potential?
Subcutaneous administration may reduce healthcare costs, improve patient adherence, and expand outpatient use.

4. What are the key risks for investors?
Regulatory delays, inability to gain market share, pricing pressures, and competitive innovations pose significant risks.

5. What is the total addressable market size for Zilucoplan?
Globally, approximately 1 million gMG patients exist, with the U.S. accounting for around 60,000. The wider complement-mediated disease market may further expand prospects.

---

References:

[1] UCB Pharma. (2022). Zilucoplan development pipeline.
[2] Myasthenia Gravis Foundation. (2022). Epidemiological data.
[3] U.S. Food and Drug Administration. (2023). Regulatory review updates.
[4] MarketWatch. (2023). Biologic drug approvals and market size.